193021-78-2

Upstream product

• 193023-01-7 2,7-dioxa-spiro[3.5]nonane-1-one 
• 59621-76-0 4-(4'-chlorophenoxy)-benzenethiol 
• 1048976-72-2 4-(4-chlorophenoxy)thiophenol sodium salt 
• 252767-81-0 4-(4'-chlorophenoxy)phenyl chloromethyl sulfide 

Relevant academic research and scientific papers

Methods for the treatment of liver diseases

Provided herein are methods for treatment of a liver disease by administering a matrix metalloproteinase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the matrix metalloproteinase inhibitor described herein. Further provided are methods for lowering an elevated level of liver enzymes by administering the matrix metalloproteinase inhibitor.

Combination therapy for the treatment of liver diseases

Provided herein are methods for treatment of a liver disease by administering a combination of a matrix metalloproteinase inhibitor and a caspase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the MMP and caspase inhibitors described herein. Further provided are methods for lowering an elevated level of liver enzymes.

Processes for preparing 3-Arylsulfur hydroxamic acids

This invention provides processes for the preparation of a compound of Formula I: Y—C(═O—C(R1)(R2)—CH2—S(O)nR3 wherein: Y is hydroxy or XONX, where each X is independently hydrogen, lower alkyl or lower acyl; R1is hydrogen or lower alkyl; R2is hydrogen, lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, or R1and R2together with the carbon atom to which they are attached form a cycloalkyl or heterocyclo group; R3is aryl; and n is 0, 1 or 2. The invention also provides novel aryl haloalkyl sulfide intermediates useful for the preparation of compounds of Formula I and novel methods of preparing aryl alkyl sulfides.

Matrix metalloprotease inhibitors

The present invention relates to compounds of Formula I: STR1 that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.

Matrix metalloprotease inhibitors

Compounds of the formula: wherein: n is0, 1 or 2; Y ishydroxy or XONH-, where X is hydrogen or lower alkyl; R1is hydrogen or lower alkyl; R2is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocylo-lower alkyl, heterocyclo-lower heteroalkyl or -NR6R7, wherein: R6is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, heteroaryl and heteroaralkyl; R7is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, -C(O)R8, -C(O)NR8R9, -SO2NR8R9, -SO2R10, aryloxycarbonyl, or alkoxycarbonyl; or R6and R7together with the nitrogen atom to which they are attached represent a heterocyclo group; wherein R8and R9are independently hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or heteroalkyl; and R10is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or heterocyclo; or R1and R2together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group; R3ishydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy; R4ishydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl; or R2and R3together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group; or R3and R4together with the carbon to which they are attached represent a cycloalkyl or heterocyclo group; and R5islower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or pharmaceutically acceptable salts or esters thereof exhibit useful pharmacological properties, in particular for use as matrix metalloprotease inhibitors, particularly for interstitial collagenases.